TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Status:
Recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in
adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each
patient, using the patient's own circulating immune cells. First, Genocea confirms which
cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune
cells that recognize these cancer proteins are multiplied many times (a process called
PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in
one or more intravenous (IV) infusions.